4,420 results on '"Schreiber, Stefan"'
Search Results
2. Dynamic changes in extracellular vesicle-associated miRNAs elicited by ultrasound in inflammatory bowel disease patients
3. FixNCut: single-cell genomics through reversible tissue fixation and dissociation
4. Die Assumptio Mosis. Studien zur Rezeption massgültiger Überlieferung (review)
5. Epidemiologische Daten und medizinische Versorgungssituation von Patienten mit chronischen Entzündungserkrankungen in Deutschland: Real-World-Evidenz zu Prävalenz, Erkrankungskombinationen, Versorgung
6. Amino acid auxotrophies in human gut bacteria are linked to higher microbiome diversity and long-term stability
7. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort
8. Trends in the epidemiology of Clostridioides difficile infection in Germany
9. Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease
10. Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial
11. Genome-wide association analysis reveals the associations of NPHP4, TYW1-AUTS2 and SEMA6D for Behçet's disease and HLA-B*46:01 for its intestinal involvement
12. Depression and fatigue six months post-COVID-19 disease are associated with overlapping symptom constellations: A prospective, multi-center, population-based cohort study
13. Effects of lifestyle and associated diseases on serum CC16 suggest complex interactions among metabolism, heart and lungs
14. Tryptophan degradation as a systems phenomenon in inflammation – an analysis across 13 chronic inflammatory diseases
15. Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
16. Serine metabolism is crucial for cGAS-STING signaling and viral defense control in the gut
17. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study
18. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
19. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure
20. Mirikizumab bei Colitis ulcerosa
21. Transethnic analysis of the human leukocyte antigen region for ulcerative colitis reveals not only shared but also ethnicity-specific disease associations.
22. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
23. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment
24. Cohort profile: the Food Chain Plus (FoCus) cohort
25. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
26. Resilienz als Resonanzfähigkeit. Ein affekttheoretischer Blick auf ein psycho-sozio-archäologisches Forschungsfeld
27. Atmungstherapie an einem Universitätsklinikum: eine Evaluation des Tätigkeitsprofils
28. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
29. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics
30. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer
31. THU-254-YI Differential gene expression profiles of liver tissue, subcutaneous and visceral adipose tissue delineates severity of MASLD in heavily obese patients
32. AMISELIMOD FOR THE TREATMENT OF ACTIVE ULCERATIVE COLITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
33. Safety, tolerability, and pharmacokinetics of single‐ and multiple‐ascending doses of olamkicept: Results from randomized, placebo‐controlled, first‐in‐human phase I trials
34. Manifestation of an immunologic dysbalance in the otological and sinunasal area based on therapeutic damage in autoimmune diseases
35. Single-cell RNA sequencing of nasal mucosa for molecular and genetic analysis of chemosensory dysfunction in post-COVID patients
36. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme
37. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
38. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study
39. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
40. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
41. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study
42. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
43. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
44. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease
45. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity
46. DNA methyltransferase 3A controls intestinal epithelial barrier function and regeneration in the colon
47. Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients
48. Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease
49. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
50. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.